Marstacimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TFPI |
| Clinical data | |
| Trade names | Hympavzi |
| Other names | PF-06741086, marstacimab-hncq |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Tissue factor pathway inhibitor (TFPI) |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6304H9766N1678O2006S44 |
| Molar mass | 142569.85 g·mol−1 |
Marstacimab, sold under the brand name Hympavzi, is a monoclonal antibody medication used for the treatment of hemophilia A and hemophilia B.[1][2][3] It is a tissue factor pathway inhibitor (TFPI) antagonist.[2] It was developed by Pfizer.[4] Marstacimab is a new type of medication that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor.[2] This increases the amount of thrombin, an enzyme that is critical in blood clotting, that is generated. This is expected to reduce or prevent the frequency of bleeding episodes.[2]
The most common side effects include injection site reactions, headache, and itching (pruritis).[2]
Marstacimab was approved for medical use in the United States in October 2024.[2]
Medical uses
[edit]Marstacimab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people aged twelve years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.[2]
Side effects
[edit]The US prescription label for marstacimab contains warnings and precautions about circulating blood clots (thromboembolic events), hypersensitivity, and embryofetal toxicity.[2]
The most common side effects include injection site reactions, headache, and itching (pruritis).[2]
History
[edit]The US Food and Drug Administration (FDA) approval of marstacimab is based on an open-label, multi-center study in 116 adult and pediatric male participants with either severe hemophilia A or severe hemophilia B, both without inhibitors.[2] For the first six months of this study, participants received treatment with replacement factor either on-demand (33 participants) or prophylactically (83 participants).[2] These participants then received marstacimab prophylaxis for twelve months.[2] The primary measure of efficacy of marstacimab was the annualized bleeding rates of treated bleeds.[2] In the participants receiving on-demand factor replacement during the first six months of the study, the estimated annualized bleeding rate was 38 compared to the estimated annualized bleeding rate during treatment with marstacimab of 3.2, showing that marstacimab was superior to on-demand factor replacement.[2] In the initial six-month period during which participants received prophylactic factor replacement, the estimated annualized bleeding rate was 7.85 and was 5.08 during the subsequent twelve months on marstacimab prophylaxis, showing that marstacimab provided similar bleeding rates.[2] The FDA granted the application for marstacimab orphan drug designation for this application.[2] The FDA granted the approval of Hympavzi to Pfizer Inc.[2]
Society and culture
[edit]Legal status
[edit]In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hympavzi, intended for prophylaxis of bleeding episodes in people aged twelve years of age and older, weighing at least 35 kilograms (77 lb), who have severe hemophilia A or B.[3] The applicant for this medicinal product is Pfizer Europe Ma EEIG.[3]
The US Food and Drug Administration approved marstacimab in October 2024, for people with hemophilia A and B patients ages twelve and older without inhibitors (to prevent or reduce bleeding episodes)[2][5][6]
Names
[edit]Marstacimab is the international nonproprietary name.[7]
Marstacimab is sold under the brand name Hympavzi.[2]
References
[edit]- ^ a b https://labeling.pfizer.com/ShowLabeling.aspx?id=20916
- ^ a b c d e f g h i j k l m n o p q r s t "FDA Approves New Treatment for Hemophilia A or B". U.S. Food and Drug Administration (Press release). 1 October 2024. Retrieved 11 October 2024.
This article incorporates text from this source, which is in the public domain.
- ^ a b c "Hympavzi EPAR". European Medicines Agency (EMA). 19 September 2024. Retrieved 21 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B". Pfizer (Press release). 9 December 2023. Retrieved 21 September 2024.
- ^ "U.S. FDA Approves Pfizer's Hympavzi (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors" (Press release). Pfizer. 11 October 2024. Retrieved 12 October 2024 – via Business Wire.
- ^ Research Cf (28 October 2024). "Novel Drug Approvals for 2024". FDA.
- ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
External links
[edit]- Clinical trial number NCT03938792 for "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |